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http://dx.doi.org/10.1016/j.jacl.2013.0Abstract: Familial hypercholesterolemia (FH) is characterized by severe elevations in low-density lip-
oprotein cholesterol (LDL-C) and poses considerable treatment challenges. Substantive LDL-C reduc-
tions are difficult to achieve with standard therapies, and many patients with FH do not tolerate
currently available lipid-lowering medications. Mipomersen is an antisense oligonucleotide injectable
drug that was recently approved by the Food and Drug Administration for the treatment of homozygous
FH. It is complementary in sequence to a segment of the human apolipoprotein (Apo) B-100 messenger
RNA and specifically binds to it, blocking translation of the gene product. Reducing the production
of Apo B-100 reduces hepatic production of very low-density lipoprotein, consequently decreasing
circulating levels of atherogenic very low-density lipoprotein remnants, intermediate-density lipopro-
teins, LDL, and lipoprotein(a) particles. Results from a pivotal trial conducted in patients with homo-
zygous FH, and supporting trials in patients with heterozygous FH with coronary artery disease (CAD)
(LDL-C $100 mg/dL, triglycerides , 200 mg/dL), severe hypercholesterolemia (LDL-C $300 mg/dL
or $200 mg/dL with CAD), and individuals at high risk for CAD (LDL-C $100 mg/dL,
triglycerides # 200 mg/dL), have indicated that mipomersen reduces all Apo B-containing atherogenic
lipoproteins. The average LDL-C reduction was.100 mg/dL in homozygous FH and severe hypercho-
lesterolemia populations. The main on-treatment adverse events were mild-to-moderate injection site
reactions and flu-like symptoms. Available data regarding the efficacy, safety and tolerability of mipo-
mersen, including results at up to 104 weeks of therapy, support the use of mipomersen for the treat-
ment of FH.
 2013 National Lipid Association.Open access under CC BY-NC-ND license.Mipomersen, an antisense oligonucleotide, constitutes a
novel approach to the management of dyslipidemia, spe-
cifically familial hypercholesterolemia (FH).1 Mipomersen
was recently approved by the Food and Drug Administra-
tion for the treatment of homozygous familial FH.2 FH isom
pted for publication February 20,
ociation.
2.004
Open access under CC BY-NC-NDcaused by inherited genetic defects resulting in severe ele-
vations in serum low-density lipoprotein cholesterol
(LDL-C).3 FH is usually an autosomal-dominant disorder
caused by a defect in the LDL receptor gene (LDLR), but
other forms also exist, including defects in the apolipopro-
tein (Apo) B gene (APOB), proprotein convertase subtilisin/
kexin type 9 gene (PCSK9), gain-of-function mutations,
and autosomal-recessive hypercholesterolemia. There are
more than 1700 documented polymorphisms in the LDLR
that affect circulating cholesterol concentrations.3 FH poses license.
Toth Emerging LDL therapies: mipomersen S7considerable treatment challenges because substantive
LDL-C reductions are difficult to achieve with standard
therapy, and a significant percentage of patients do not tol-
erate the currently available lipid-lowering medications
such as statins. More novel approaches to lipid lowering
are needed in patients with homozygous or heterozygous
FH who often require complex combinations of therapies
(including LDL apheresis, statins, bile acid binding resins,
niacin, and/or cholesterol absorption inhibition) but still do
not achieve their LDL-C goals.Antisense oligonucleotide technology
Disease states are often characterized by an abnormal
protein or enzyme. There are many etiologies for hyper-
cholesterolemia, one of which is an increase in the activity
of the 3-hydroxy-3-methylglutaryl coenzyme A reductase
enzyme causing increased cholesterol biosynthesis.4 As
their name implies, the 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors (statins), inhibit the rate-
limiting enzyme for cholesterol biosynthesis. However,
drugs created through antisense technology act differently
from traditional enzyme or protein-targeting drugs.5,6 In an-
tisense technology, the target gene is transcribed normallyFigure 1 Mechanism of action of an antisense oligonucleotide. DN
 Copyright Antisense Therapeutics Limited, 2012. Accessed at http:
permission from Antisense Therapeutics Limited.from DNA to mRNA, but the mRNA is then intercepted
by an antisense oligonucleotide with which it undergoes a
Watson-Crick type hybridization reaction so that the
mRNA can no longer be translated into a protein
(Fig. 1).5,6 A successful antisense molecule engages in
Watson-Crick hybridization and provides steric hindrance.
In addition, the antisense complex becomes a target for
RNase H, an enzyme that cleaves and destroys the
mRNA-antisense oligonucleotide hybrid.Mipomersen
Mipomersen is a 20-mer of nucleotides (polynucleotide
of 20 bases) that is complementary in sequence to a
segment of human Apo B-100 mRNA. It specifically binds
to Apo B-100 mRNA, blocking the translation of the gene
product.5–8 Mipomersen is composed of a phosphorothioate
backbone (an oxygen atom is substituted with a sulfur
atom along the phosphate backbone), and it has 20-O-
(2-methoxyethyl)-modified ends which provide greater
biological stability and higher binding affinity to the target
mRNA compared with earlier antisense technologies.5–8
Antisense drugs in general, and mipomersen in partic-
ular, are largely distributed to the liver after injection, whichA, deoxyribonucleic acid; mRNA, messenger ribonucleic acid.
//www.antisense.com.au/technology-overview/ and reprinted with
S8 Journal of Clinical Lipidology, Vol 7, No 3S, June 2013is where Apo B-100 is synthesized. Reducing the synthesis
of Apo B-100 consequently decreases the production
of very-low-density lipoprotein (VLDL) particles.9 After
VLDL particle secretion into the circulation, lipoprotein
lipase and hepatic lipase progressively hydrolyze trigly-
cerides (TG) within the VLDL particle core, forming
intermediate-density lipoprotein particles and progressively
smaller species of LDL. Thus, reducing Apo B-100 biosyn-
thetic capacity with mipomersen decreases circulating
levels of a spectrum of atherogenic Apo B–containing lipo-
proteins. Mipomersen is catabolized by endonucleases and
exonucleases, which are ubiquitously expressed in all cells
and tissues, and is largely excreted in the urine.8,10 It has
no dependency on cytochrome P450 metabolism; conse-
quently, there is little potential for interaction with statins,
ezetimibe, bile acid binding resins, or other lipid lowering
medications with which it might be used in combination.8,10Phase 3 clinical trials of mipomersen
To date, four phase 3 trials of mipomersen have been
completed in the following patient populations: (1) homo-
zygous FH, which occurs in 1 of 1,000,000 people11;
(2) heterozygous FH in patients with coronary artery dis-
ease (CAD)12; (3) severe hypercholesterolemia (as defined
later in this section)13; and (4) hypercholesterolemia in pa-
tients at high risk for CAD (as defined later in this sec-
tion).14 The final population is a particularly large target
because many patients with excessive atherogenic lipopro-
tein burden are at high risk for CAD, but do not, or believe
they cannot, tolerate statins and other lipid-altering medica-
tions. All of these phase 3 trials were randomized, double-
blind, placebo-controlled, multicenter studies and in each
the patients were already on stable dose(s) of their maxi-
mally tolerated lipid-lowering therapies.11–14 Patients
were administered weekly subcutaneous injections of pla-
cebo or 200 mg mipomersen for 26 weeks and were given
the option to self-administer the drug. Twice as many pa-
tients were randomized to mipomersen compared with pla-
cebo. The primary efficacy end point was the percent
change in LDL-C from baseline to week 28 (2 weeks after
the last dose), and secondary end points included percent
changes in Apo B, total-C, non–high-density lipoproteinTable 1 Efficacy of mipomersen added to maximally tolerated lipid-
Patient population
Baseline LDL-C,
mg/dL
Per
LD
Homozygous FH11 439 22
Severe hypercholesterolemia13 276 23
Heterozygous FH 1 CAD12 153 22
Hypercholesterolemia 1 high risk
for CAD14
123 23
Apo B, apolipoprotein B; CAD, coronary artery disease; FH, familial hyp
low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); TG, triglycerides.(non-HDL)-C, TG, lipoprotein (a) [Lp(a)], VLDL, Apo
A1, HDL-C, and the LDL-C/HDL-C ratio. Safety follow-
up assessments were performed 24 weeks after the primary
efficacy end point measurement, ie, week 52.
The diagnosis of homozygous FH (n 5 51) was
confirmed by genetic testing or a clinical diagnosis of
untreated LDL-C .500 mg/dL plus either xanthomas
before 10 years of age or evidence of heterozygous FH in
both parents (ie, compound homozygotes).11 Classification
of patients as having heterozygous FH with CAD (n5 124)
required LDL-C $100 mg/dL, TG , 200 mg/dL, and a
diagnosis of CAD.12 The diagnosis of severe hypercholes-
terolemia (n 5 58) was based on an LDL-C level
$300 mg/dL or $200 mg/dL with CAD,13 and individuals
at high risk for CAD (n 5 158) were required to have
LDL-C$100 mg/dL and TG, 200 mg/dL.14 Among these
populations, patients were relatively evenly split between
men and women (w43% to 63% male) and mean age
ranged from 31 to 59 years. Notably, between 42% and
90% of patients were on a statin plus another lipid-
lowering drug, which demonstrates that despite the use of
combination therapy, many patients fail to achieve their
LDL-C treatment goals.
Percent changes in LDL-C, Apo B, Lp(a), TG, and
HDL-C in response to mipomersen treatment in the four
phase 3 studies are presented in Table 1.11–14 Patients
with homozygous FH and those with severe hypercholester-
olemia achieved an average LDL-C reduction from baseline
(above that achieved by maximum tolerated lipid-lowering
therapies) of .100 mg/dL, representing 25% and 36%
LDL-C reductions, respectively (P , .001 for both).
Among patients with heterozygous FH and CAD, 45%
achieved a target LDL-C of ,100 mg/dL, and 51% of
patients with hypercholesterolemia and high risk for CAD
achieved a target LDL-C of ,70 mg/dL. Typically,
the maximal steady-state LDL-C reduction was achieved
at 12-16 weeks (Fig. 2).11 Responses in other lipid variables
were also favorable; notably Lp(a) was reduced by
24%-33% across patient populations.
In a pooled analysis of phase 3 trials, 18.0% of
mipomersen-treated individuals and 2.3% of placebo-
treated individuals discontinued due to an adverse event
or serious adverse event.15 The most common adverse
events leading to discontinuation with mipomersenlowering therapies in phase 3 trials
centage change from baseline
L-C Apo B Lp(a) TG HDL-C
5 227 231 218 115
6 236 233 29 16
8 226 221 214 13
7 238 224 226 12
ercholesterolemia; HDL-C, high-density lipoprotein cholesterol; LDL-C,
Figure 2 Change in LDL-C over time with 26 weeks of mipomersen treatment in a phase 3 trial in patients with homozygous FH.
Reprinted with permission from Raal et al.11 LDL, low-density lipoprotein.
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and flu-like symptoms. Bilirubin indices, serum albumin,
and prothrombin times were not altered by mipomersen
treatment, and 8% of mipomersen-treated patients had an
alanine aminotransferase level greater than three times the
upper limit of normal on two consecutive occasions, seven
days apart. Mipomersen has typically been shown to mod-
estly increase hepatic fat (ie, steatosis) generally in the
range of 6%-12%.12,14,16 However, this effect was reversi-
ble after cessation of therapy, and as described in more de-
tail in the section to follow, long-term extension studies
have shown that in some patients hepatic fat decreases
over time with mipomersen use.9,15,17 There were no clini-
cally significant drug–drug interactions between mipo-
mersen and statins or ezetimibe, ie, no P450 inhibition of
activation, no P-glycoprotein impact, and no protein-
binding interactions with statins.10 There were also no sig-
nificant interactions between mipomersen and warfarin, and
no changes in the QT interval.15Extension trial data with mipomersen
A 104-week open-label extension of three phase 3
mipomersen studies (in patients with homozygous FH,
heterozygous FH, and severe heterozygous FH) is ongo-
ing.17 A total of 141 patients were enrolled. At the time of
an interim analysis, 17 patients had completed treatment,
69 had discontinued, and 55 were continuing treatment.
The interim results indicated sustained reduction of
LDL-C, Apo B, Lp(a), non-HDL-C, and TG levels extend-
ing up to 2 years. The safety and tolerability profile
remained consistent with the original phase 3 results,
with the exception of the effects on liver fat. Whereas in-
creased steatosis was observed in shorter trials,12,14,16
long-term clinical follow-up showed a return to normal
levels of liver fat over time.9,15,17Conclusion
To summarize, the results from phase 3 clinical trials,
when added to maximally tolerated lipid-lowering drug
therapy, mipomersen administration induced reductions in
all Apo B-containing atherogenic lipoproteins. The average
LDL-C reduction exceeded 100 mg/dL in homozygous FH
and severe hypercholesterolemia populations. The effects
were consistent across all patient populations. Frequently
observed on-treatment adverse events were mild-to-
moderate injection-site reactions and flu-like symptoms.
These efficacy, safety, and tolerability results indicate
mipomersen is suitable for use in the target patient popu-
lation, and provide promise for the management of FH and
severe hypercholesterolemia. The use of mipomersen in
conjunction with LDL apheresis is currently being inves-
tigated in a phase 3 clinical trial in Germany to determine
whether mipomersen will result in reduced apheresis time
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